Biognosys, Siemens Healthineers Collaborate on Diagnostic Biomarker Development

Under the agreement, Biognosys will leverage its biomarker discovery technologies in conjunction with Siemens’ biomarker assay development, lab testing, and commercialization infrastructure to discover novel biomarkers followed by translation of the biomarkers into validated assays for potential clinical applications.

Machine Learning Method Predicts New Cancer Genes

Known as Explainable Multi-Omics Graph Integration (EMOGI), the machine learning method predicted 165 new cancer genes by combining multiomics pan-cancer data—such as mutations, copy number changes, DNA methylation and gene expression—together with protein–protein interaction (PPI) networks.
A close-up of a mother and father holding a newborn baby son at home.

Orchid Launches First Pre-Conception Test Based on Genetic Risk Scores

Orchid’s Couple Report is a home-based test that reveals if a couple is at elevated risk of passing on 10 diseases: heart disease, stroke, atrial fibrillation, schizophrenia, Alzheimer's Disease, breast cancer, prostate cancer, type 2 diabetes, type 1 diabetes, and inflammatory bowel disease.
Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. [Source: © Alex Tihonov/Fotolia]

Novel Biomarker Could Aid Development of Drugs for Age-Related Disorders

The biomarker is a signaling lipid metabolite oxylipin molecule that normally accumulates inside cells, but is released when senescent cells die, which makes it detectable in urine and blood, and could aid the development of senolytic drugs against a range of chronic age-related conditions, such as arthritis, Alzheimer’s disease, and glaucoma.
DNA strand and Cancer Cell

Early Cancer Recurrence Detection: A Tumor-Informed Approach

Join us for this live Clinical OMICs webinar, sponsored by Natera, for a dynamic discussion with our esteemed guests Dr. Gregory Botta from UC San Diego and Dr. Angel Rodriguez from Natera, who will review the value of a tumor informed approach to optimize patient management in the adjuvant treatment setting.
Pregnancy Bump

Loss of Endometrial Stem Cells Prior To Conception Raises Miscarriage Risk

Highly proliferative mesenchymal stem cells are recruited into the lining of the womb at the time of embryo implantation. These cells appear critical in pregnancy to accommodate the rapidly growing placenta and fetus and are depleted in women with recurrent pregnancy loss, according to new U.K. research.
Genetic research, conceptual illustration

New Technique Traces Origin of DNA in Blood Test

Genetic-Epigenetic Tissue Mapping determines the tissue of origin of DNA in a blood sample by comparing genetic and methylation profiles from relevant tissues. The researchers suggest that this method could be used in prenatal screening, to monitor organ transplant rejection, or test for as yet undetected cancers.
cancer cell

pH-Based Imaging Plus Machine Learning Identifies Cancerous Cells

Researchers have developed a method of quickly identifying cancer cells based on their pH using specialized acidity-based imaging and machine learning. This technique could be used to detect a few cancerous cells among many healthy cells, which could help provide a more accurate prognosis and better reflect the impact of cancer treatment.
Biodesix has expanded its lung disease test franchise by acquiring Intagrated Diagnostics (Indi)

Biomarker Testing for NSCLC Shows Wide Variability

The introduction of new biomarkers and innovative testing methods—like whole-genome sequencing and the evaluation of circulating tumor DNA using liquid biopsies—makes complex diagnosis in patients with stage IV non–small cell lung cancer likely to be even more complex.  
Pancreatic cancer, malignant tumor of pancreas

New Biomarker of Pancreatic Cancer May Predict Benefit of Tumor-Penetrating Peptide

According to the new study, the tumor-penetrating peptide known as iRGD appears to enhance the effects of chemotherapy, reducing metastasis, and increasing survival, to a degree determined by levels of β5 integrin. Essentially, β5 integrin gives chemotherapeutic agents the opportunity to destroy the tumor from within.
Scroll Up